Everolimus in metastatic breast cancer (MBC): Clinical experience as a late treatment line.

e11526 Background: Everolimus, in combination with exemestane, is indicated to treat hormone receptor-positive, HER2-negative metastatic breast cancer (MBC), in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. However, efficacy of everolimus as a late treatment line in MBC has not been sufficiently explored. We report here our experience with everolimus in patients (pts) pretreated by a median of 3 chemotherapy (CT) and 2 hormonotherapy (HT) lines in the metastatic setting. Methods: Between 2012 and 2014, 63 MBC pts progressing under HT (30 pts) or after CT (32 pts) received a combination of everolimus and HT (EHT) for a median duration of 27.8 weeks. Overall survival (OS) was calculated from the onset of EHT, to last report or death. Results: At the cutoff date (February 2014), median OS was not reached after a median follow up of 18 months;18 patients had died. At 12 months, the survival rates were respectively 100, ...